SynthesisLower urinary tract symptoms2026
Sexual Function and Clinical Outcomes Following Rezūm Therapy for Benign Prostatic Hyperplasia: An Updated Systematic Review Including Large Prostate Volumes.
Synthesis in Lower urinary tract symptoms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate sexual function and clinical outcomes following Rezūm water vapor thermal therapy (WVTT) for benign prostatic hyperplasia (BPH), with a dedicated focus on patients with large prostate volumes (> 80 mL).
methodsA systematic search on PubMed, Scopus, and EBSCOhost was conducted through June 23, 2026. Studies reporting validated patient-reported outcome measures for erectile (IIEF) and ejaculatory (MSHQ-EjD) functions were included. Methodological quality was appraised using the Newcastle-Ottawa Scale (NOS) for 27 cohorts and the Cochrane RoB 2 tool for three randomized controlled trials (RCTs).
resultsThirty studies (N = 4635 patients) met inclusion criteria. Across gland sizes (30-150 mL), Rezūm demonstrated a consistent trend toward preservation of erectile and ejaculatory function. Although several studies reported statistically significant improvements in IIEF scores, these generally did not reach established thresholds for clinical significance. Ejaculatory function was preserved in the majority of patients, contrasting with high rates of ejaculatory dysfunction reported for resective comparators. Ten studies provided data for prostates > 80 mL; in this subgroup, Rezūm provided significant relief of lower urinary tract symptoms (LUTS) with sexual function outcomes that appeared comparable to those in standard-sized glands. Adverse events were predominantly Clavien-Dindo Grade I-II, with Grade ≥ III complications occurring in < 1% of patients. Overall, methodological quality was limited, with a high prevalence of low-to-moderate quality evidence, and all RCTs judged at high risk of bias.
conclusionsCurrent evidence suggests that Rezūm preserves erectile and ejaculatory function while providing meaningful relief of urinary symptoms, including in large-volume prostates. However, confidence in these findings remains limited by the predominance of low-quality evidence and a high risk of bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.